Latest News for: alks

Edit

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alaska Air Group, Inc. - ALK

PR Newswire 11 Dec 2025
NEW YORK, Dec ... ("Alaska Air" or the "Company") (NYSE. ALK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 ... [Click here for information about joining the class action] ... 7980 ... 21% ... .
Edit

ALK Investors Have Opportunity to Join Alaska Air Group, Inc. Fraud Investigation with the Schall ...

Nasdaq Globe Newswire 10 Dec 2025
ALK Investors Have Opportunity to Join Alaska Air Group, Inc. Fraud Investigation with the Schall Law Firm ... .
Edit

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America

Nasdaq Globe Newswire 01 Dec 2025
ALK (ALKB.DC / OMX. ALK B) today announced the appointment of Edward Jordan as new Executive Vice ...
Edit

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America (ALK-Abelló A/S)

Public Technologies 01 Dec 2025
2025-12-01 15.35.00 CET ALK-Abelló - Changes board/management/auditors ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America. ALK (ALKB.DC / OMX ... "I'm honoured to join ALK at this pivotal moment ... ALK-Abelló A/S.
Edit

SMALL ALK

Calhoun Times 29 Nov 2025
PARENTING . ADVICE ....
Edit

FDA Greenlights Ensartinib: China’s Innovative ALK Inhibitor Enters Global First-Line Lung Cancer Therapy

Pharmiweb 21 Nov 2025
Ensacove) for the treatment of ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have not received prior ALK inhibitor therapy ... Increasing Importance of ALK Targeting.
Edit

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

PR Newswire 17 Nov 2025
h Includes responses in patients with compound ALK mutations (≥2 ALK mutations, cis allelic configuration not determined in all cases) after ≥ 2 prior ALK TKIs (ORR = 58% [25/43, including 1 uPR] with DOR ≥ 12 months of 69% [95% CI.
Edit

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC (Nuvalent Inc)

Public Technologies 17 Nov 2025
Any prior ALK TKI ... h Includes responses in patients with compound ALK mutations (≥2 ALK mutations, cis allelic configuration not determined in all cases) after ≥ 2 prior ALK TKIs (ORR = 58% [25/43, including 1 uPR] with DOR ≥ 12 months of 69% [95% CI.
Edit

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC ...

The Galveston Daily News 14 Nov 2025
Company to host webcast and conference call on November 17, 2025 at 8.00am ET ....
Edit

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

PR Newswire 14 Nov 2025
ET, to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial.
Edit

ALK upgrades its full-year outlook (ALK-Abelló A/S)

Public Technologies 12 Nov 2025
2025-11-12 17.16.44 CET ALK-Abelló - Inside information ALK upgrades its full-year outlook ... ALK (ALKB.DC / OMX ... ALK-Abelló A/S ... This information is information that ALK is obliged to make public pursuant to the EU Market Abuse Regulation. About ALK.
Edit

ALKS Narcolepsy Type 2 Phase 2 Data Slides FINAL 11 12 2025 (Alkermes plc)

Public Technologies 12 Nov 2025
). Vibrance-2 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 2.. Positive Topline Results. November 12, 2025. Vibrance-2. Successful Phase 2 Study of Alixorexton in Patients With Narcolepsy Type 2 ... key objectives.. Efficacy ... ALKS 2680-301 ... 0. 2.
Edit

Nine-month interim report (Q3) 2025 (unaudited) (ALK-Abelló A/S)

Public Technologies 12 Nov 2025
2025-11-12 17.22.11 CET ALK-Abelló - Interim report (Q1 and Q3) Nine-month interim report (Q3) 2025 (unaudited). ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 ... ALK-Abelló A/S.
Edit

Invitation to the presentation of ALK's first nine months (Q3) 2025 results on Thursday, 13 November 2025 (ALK-Abelló A/S)

Public Technologies 06 Nov 2025
2025-11-06 17.01.46 CET ALK-Abelló - Investor News Invitation to the presentation of ALK's first nine months (Q3) 2025 results on Thursday, 13 November 2025. ALK (ALKB.DC / OMX ... ALK-Abelló A/S ... About ALK ... Find more information at www.alk.net.
Edit

Nesušalk.lt: How one knitter brought Lithuanian warmth online (Kaunas University of Technology)

Public Technologies 06 Nov 2025
). There are plenty of stories with happy endings, but fewer where a personal hobby grows into a meaningful business ... What began as a simple pastime soon turned into a creative outlet and a small business ... First lessons from YouTube ... gražus-vardas.lt.

Article Search

tools
×
×
×
×